VNS yields results that suggest potential utility in the management of Lennox-Gastaut Syndrome, and the analysis suggests greater effectiveness for atonic seizures (drop attacks), followed by tonic and absence seizures.
Abstract
Background
This study evaluates the efficacy and safety of Vagus Nerve Stimulation (VNS) in the treatment of refractory Lennox-Gastaut Syndrome (LGS) in pediatric patients.
Methods
A systematic literature review was conducted based on observational studies and case series analyses, followed by assessment of risk of bias using the ROBINS-I tool.
Results
The results demonstrated that, among the combined sample of 527 patients included in the selected studies, 375 achieved a reduction greater than 50% in seizure frequency after VNS therapy, with some cases reporting complete seizure remission. The analysis suggests greater effectiveness for atonic seizures (drop attacks), followed by tonic and absence seizures. Regarding secondary outcomes, significant qualitative improvements were reported in alertness, attention, and sleep quality. Although the intervention appears to be relatively safe, the included studies presented a high risk of bias in the outcome measurement domain, mainly due to the impracticality of blinding in surgical procedures and the subjective nature of caregiver-reported outcomes. The heterogeneity of clinical responses appears to be associated with differences in stimulation parameters and variability in baseline clinical conditions.
Conclusion
VNS yields results that suggest potential utility in the management of LGS. While the ideal scenario would require randomized clinical trials with representative and exclusive samples for the syndrome, as well as standardized stimulation protocols, it is understood that methodological limitations exist when dealing with a rare syndrome. Therefore, the importance of this systematic review is highlighted in order to encourage individualized and assertive clinical decisions in the management of these patients.
A significant trend toward improved seizure outcomes and change in quality of life was observed with longer treatment durations, and no significant differences were observed in overall ASM load between baseline and any follow-up visit.
Patients with disorders of consciousness (DOC) have limited options for arousal-promoting interventions. Transcutaneous auricular vagus nerve stimulation (taVNS), a non-invasive neuromodulation technique, has shown potential to improve conscious behaviors in a subset of patients with DOC. However, substantial interindi...
Wei-Hang Zhai, Yi-Fei Wang, Meng Li et al.· Frontiers in Human Neuroscie...· 0 citations
OBJECTIVE
Implanted vagus nerve stimulation (VNS) is an established treatment for drug-resistant epilepsy. However, stimulation-related voice disturbances are among the most frequently reported adverse effects. This systematic review and meta-analysis synthesized available evidence regarding voice outcomes associated w...
Aylén Chiara Fernández, Germán Gálvez-García, Adrián Pérez del Olmo et al.· Journal of Voice· 0 citations
Objectives Transcutaneous auricular vagus nerve stimulation (taVNS) has been proposed as a non-pharmacological intervention for postoperative pain, but its effects remain unclear. We conducted this study to evaluate the efficacy and safety of taVNS for postoperative pain management. Methods A systematic literature sear...
Zheng-Chun Mao, Yue-Zhong Lv, Qi-Hong Shen et al.· Journal of Pain Research· 0 citations
BACKGROUND
Lennox-Gastaut syndrome (LGS) is a severe, drug-resistant developmental and epileptic encephalopathy for which corpus callosotomy (CC) can be a particularly effective option for seizure control. However, this benefit must be weighed against the tradeoff of permanent corpus callosum disconnection. Although us...
Debopam Samanta, P. Ramani, Taylor J. Abel et al.· Epilepsy Research· 0 citations
Introduction. Trigeminal neuralgia (TN) is a chronic neuropathic pain disorder characterized by recurrent, evocable, unilateral brief, electric shocklike pains with an abrupt onset and cessation, substantially impacting quality of life. Although pharmacotherapy is the first-line treatment, a subset of patients remains...
Unknown authors· Advancements in Health Resea...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.